GVHD, whereas donor cell inocula that appeared to preferentially react by their alloreactive T suppressor (T s) cells caused the suppressive pathological symptoms of acute GVHD (2-4, 7, 8, 10) . Moreover, when unselected donor T cells were injected into F1 recipients, which differed solely at class II H-2 antigens (I-A/I-E), exclusively stimulatory GVHD was found; in contrast, a difference in the Fl recipients at both class I (H-2 K/D) and class II antigens was needed for the induction of acute GVHD (3, 8) . Neither clear-cut stimulatory nor suppressive GVH symptoms were found in those FI recipients that differed from the donor solely at class I H-2 antigens (3) .
From studies on the allogenetic effect in vitro it is known that class II (I-A/I-E) antigenic differences activate Lyt-1 +2-T H cells, which then provide maximal allohelp (12, 13) . By contrast, the activation of alloreactive T s cells requires the presence of Lyt-l+2 + cells as well as incompatibility, on the allogeneic B cells, at class I H-2 antigens (12, 13) . Moreover, it seems from these studies in vitro that in order to become fully activated, the class I-reactive Lyt-l+2 ÷ T s cells must be induced by class I I-reactive Lyt-1 ÷2-cells (13, 14) . These findings suggest that the class II (I-A/I-E) incompatibilities in the F1 recipients previously studied (3, 8) 
selectively activated the alloreactive T H cells out of the pool of unselected donor T cells; the activated T H cells might then have caused the formation of SLE-like autoantibodies and the development of other stimulatory GVH symptoms. In contrast, an incompatibility in the Fl recipient at both class II (I-A/I-E) and class I (K/D) antigens might have activated both the class II-reactive T H or inducer cells and the class I-reactive T s effector cells (3)
. It should be noted here that alloreactive donor T s cells, and not cytotoxic T cells, appear to be important effector cells in acute GVHD. These T s cells seem to be the effector cells, because they suppress the physiologic proliferation of lympho-hemopoietic cells and thus cause the pancytopenia of acute GVHD (4) .
The intra-H-2 requirements for the induction of either stimulatory (chronic) GVHD or suppressive (acute) GVHD (3, 8) parallel those for the induction of positive and negative allogeneic effects in vitro (12, 13) . The missing link between the studies performed in vitro and the GVH experiments in vivo concerns the Lyt subsets of donor T cells that are required for the induction of either stimulatory or suppressive GVHD. We therefore injected different Lyt subsets of B10 donor T cells into (B10 X DBA/2)F1 (BDFI) mice. The results indicate that Lyt-l+2 -T cells are able to induce SLE-like GVHD, but are incapable of inducing acute GVHD and LGVHD. The induction of acute GVHD and LGVHD on the other hand required unseparated donor T cells, which comprise both Lyt-l+2 -and Lyt-l÷2 + cells. Preparation of Donor Cells. For induction of GVHR, single-cell suspensions of donor spleen and lymph node cells were prepared, as described (7) .
Materials and Methods
Monoclonal Antibodies. Monoclonal murine anti-Lyt- 
Pretreatment of Donor Cells with Monoclonal Antibodies and Complement (C). Donor cells
consisted either of spleen cells or of a mixture of spleen cells (2 parts) and lymph node cells (1 part). For treatment with antiserum, cell suspensions were prepared in Hepesbuffered RPMI 1640 that contained 5% fetal calf serum. Suspensions of 3 x 107 live cells/ml were incubated for 45 rain on ice with either anti-Thy-l.2 serum, diluted 1 in 1,000, or anti-Lyt-l.2 or anti-Lyt-2.2 serum, each diluted 1 in 3,000. As a control, cells were treated with normal mouse serum (NMS) diluted 1 in 3,000. After incubation, the cells were spun down and resuspended with 6 ml rabbit C, which had been selected for low cytotoxicity and was diluted 1 in 12 in Hepes-buffered RPMI 1640 (not containing fetal calf serum). The suspensions were incubated for 45 min at 37 °C, and thereafter the cells were washed three times. In some experiments the donor cells were treated twice with antisera and C, according to this procedure. Hereafter, cells treated with anti°Lyt-1.2 and C, anti-Lyt-2.2 and C, anti°Thy-l.2 and C, or NMS and C will be referred to as anti-Lyt-l-, anti-Lyt-2°, anti°Thy-l-, and NMS-treated cells, respectively. Unless mentioned otherwise, these cells had been treated once.
Nylon-wood Passage of Pretreated Donor Cells.
In one experimental approach, B 10 spleen cells, which had been pretreated twice with either NMS or anti-Lyt antibodies, were passed through nylon-wool columns (13) in order to reduce the fraction of non-T cells.
Induction of GVHR.
All donor cells were injected intravenously. In the first experiment ( Fig. I and Table I ) nonirradiated mice were used as recipients. In the second experiment ( Fig. 3 and Table II ) the prospective BDF~ recipients were first irradiated with 750 rad by using 662-KeV gamma rays, emitted from a ~37Cs source (gammator, model 381, Isomedic) at a dose of 375 rad/min. Within the next 3 h, these mice were repopulated with 3 x 107 live untreated spleen cells obtained from syngeneic (BDF~) donors; 1 d later, the GVHR was induced by injection of B10 T cells. The donor cell inocula are specific in the results section.
Primary Anti-Sheep Erythrocyte (SRBC) Response. The primary plaque-forming cell (PFC) response to SRBC in vitro was performed as described elsewhere (13) .
Clinical Signs of GVHR. Twice a week, the F1 mice undergoing GVHR (GVH Fi) were inspected for symptoms of acute GVHD, such as weakness, diarrhea, and ruffled fur; weight loss was determined by weighing the mice weekly. The number of dead mice was recorded. Anemia was determined by two-weekly measurements of hematocrit. At weekly intervals, the GVH F~ mice were tested for elevated proteinuria (5300 mg protein per 100 ml urine) by means of Albustix test sticks (no. 2872, Ames, Div. of Miles). Elevated proteinuria in GVH F1 mice is a reliable indicator of ICGN (9) .
Detection of Autoantibodies.
The presence ofautoantibodies in the serum was determined at two-weekly intervals, starting at week 2 and lasting until week 16 after the initiation of the GVHR. Autoantibodies to erythrocytes were detected by the direct Coombs' test using anti-mouse IgG serum, as described (7) . Autoantibodies to thymocytes were detected by a C-dependent cytotoxicity test, as described (7); using 5~Cl-labeled thymocytes of normal BDF 1 mice as target cells. Mice were scored positive for autoantibodies against thymocytes when a 1 in 5 dilution of their serum lysed 40% or more of the target cells. IgG antibodies against nuclear antigens were detected by an indirect immunofluorescence technique using cryostat sections of mouse liver as antigenic substrate, as described (7) . IgG autoantibodies against double-stranded DNA (dsDNA) were determined by an indirect immunofluorescence technique using the extranuclear dsDNA of Crithidia luciliae as antigenic substrate, as described (7) . For the determination of both antinuclear and anti-dsDNA antibodies, the initial dilution of mouse serum was 1 in 10; the highest serum dilution at which specific immunofiuorescence was seen was called the titer. with various inocula, each of which contained 10 a viable B 10 cells. As expected, the vast majority (73%) of the F1 recipients of B10 cells that had been treated once with NMS succumbed to a typical acute GVHD (Fig. 1A) ; their LGVHD was always preceded by a 20-30% reduction of the hematocrit values (hematocrit values of N FI mice ranging from 43 to 48). None of the FI recipients of antiThy-l-treated B10 cells developed acute GVHD, not to mention LGVHD ( Fig.  1 A) ; consistent with this observation, the hematocrit values of these F~ recipients were normal (ranging from 42 to 48). Treatment of the B10 donor cells with anti-Lyt-2 completely abolished their capacity to induce acute GVHD and LGVHD; none of the GVH F] mice of this group had reduced hematocrit values. After a single treatment of the B10 donor cells with anti-Lyt-1, one-third of the FI recipients still developed acute GVHD (hematocrit values between 30 and 35) and eventually died from acute GVHD (Fig. 1 A) . After the donor cells had been treated twice with anti-Lyt-1, however, the inoculum of 108 viable B10 cells had lost its capacity to induce LGVHD ( Fig. 1 B) and even acute GVHD (hematocrit values ranging from 43 to 48). Donor cells, which had been treated twice with Lyt * All mice received a total of 10 s viable donor cells; the cells were administered in two equal portions on day 0 and day 7. The original donor-cen inocula were composed of 2 parts of spleen cells and 1 part of lymph node cells. ;t Unless mentioned otherwise, the donor cell inocula were pretreated once. After treatment, all inocula were adjusted to the number of viable cells. ! Represents the number of mice that did not die from acute GVHD (see Fig. 1 ). Group 1, 2, 3, and 5 initially consisted of 15 recipient mice; group 4 initially consisted of 10 recipient mice. I Range of maximal titers in positive mice. I Mice showing elevated proteinuria for at least 3 subsequent weeks as well as distinct granular deposits of IgG along the glomerular basement membrane when examined by immunofiuorescence technique, as described elsewhere (9).
Results

Lyt Subsets of Donor T Cells Involved in the Induction of LGVHD in Nonirradiated
SUBSETS OF DONOR T CELLS IN GVH REACTIONS
NMS, had retained their capacity to induce LGVHD (Fig. 1B) . These findings indicate that the donor T cells involved in the induction of acute GVHD must be Lyt-2 ÷ as well as Lyt-1 +.
The Donor T Cells That Cause SLE-Like GVHD in Nonirradiated F1 Recipients Carry
the Lyt-l+2 -Phenotype. The above-described nonirradiated F1 recipients, which had been studied for acute GVHD and LGVHD, were also studied for the development of SLE-like GVHD (Table I ). In addition, we studied control groups, each of which consisted of eight syngeneically injected BDF1 or B10 recipient mice. The syngeneic cells injected were either NMS-, anti-Lyt-l-, or anti-Lyt-2-treated. None of these control mice produced antibodies to thymocytes, erythrocytes, or dsDNA, let alone developed ICGN. Only one or two animals out of each of these groups produced autoantibodies against nuclear antigens. The maximal titer of these antibodies ranged from 1 in 40, to 1 in 160 (data not shown). All groups of FI mice injected with antiserum-treated B10 donor cells initially consisted of 10 or 15 mice but, as already described in Fig. 1 , many of the FI recipients in groups 1 and 3 of Table I had died from acute GVHD before the end of the experiment (week 16 after the first administration of B10 cells). However, none of these mice showed detectable amounts of lupus-like autoantibodies in their sera or had developed elevated proteinuria as a sign of ICGN (data not shown).
Group 5 in Table I shows that treatment with anti-Lyt-2 rendered the B10 cells capable of inducing an SLE-iike autoimmune disease in the BDF~ recipients. Already 2 wk after the first injection of donor cells, 53% of the FI mice had autoantibodies to thymocytes, nuclear antigens, and erythrocytes. At 4 wk after the induction of the GVHR, 100% of the F1 recipients had autoantibodies to thymocytes and nuclear antigens in their serum, and 93% were Coombs'-positive. All F1 recipients in this group remained positive for autoantibodies to thymocytes and nuclear antigens until week 16. Moreover, 40% of the F1 recipients had autoantibodies to dsDNA in their serum at one or more times tested; and severe ICGN, as indicated by elevated proteinuria and immunofluorescence studies, was observed in 33% of the F1 recipients.
In marked contrast, none of the other GVH Fl mice shown in Table I (groups 1 to 4) had comparable symptoms of SLE-like GVHD. None of them showed elevated proteinuria or immunohistoiogical evidence of ICGN, and none of them had autoantibodies against erythrocytes and dsDNA. The titers of antinuclear antibodies, if present at all, did not exceed the titers found in syngeneically injected control mice. Although the percentage of GVH F~ mice with antinuclear antibodies was increased in the F~ recipients of NMS-treated BI0 donor cells (group 1), this percentage (50%) represents only two long-term survivors out of the initial group of 15 GVH F~ mice. As expected, treatment of the B10 donor cells with anti-Lyt-1 did not render them capable of inducing SLE-like GVHD (groups 3 and 4).
Subpopulations of Donor T Cells Involved in the Induction of LGVHD in Irradiated Fi
Recipients. Since "-,70% of the peripheral T cells in the mouse express the Lyt-2 antigen (l 5), the total number of T cells among 108 viable Lyt-2-depleted B 10 cells comprised only about one-third of the total number of T ceils in NMStreated cells. This total number of donor T cells after the anti-Lyt-2 treatment might therefore have been too low to induce acute GVHD and thus caused SLElike GVHD in the nonirradiated F1 recipients used. This explanation is unlikely though because small doses of untreated B10 donor cells (5 x 106 to 30 x 10 6, 2 parts spleen cells and 1 part lymph node cells) induced only a limited autoantibody formation and failed to induce SLE-like GVHD (data not shown). To further exclude this possibility comparable numbers of viable antiserum-treated B10 T cells were injected into irradiated BDF~ recipients. In order to adjust the various donor cell inocula to comparable numbers of viable T cells, B 10 spleen cells that had been treated twice with either NMS, anti-Lyt-l, or anti-Lyt-2, were passed through nylon-wool columns.
First, we determined the ailoreactivity of these three suspensions of B10 T cells by means of the primary anti-SRBC response in vitro (Fig. 2) . Low numbers of NMS-treated B10 T cells induced aIlobelp; higher numbers induced allosuppression. The anti-Lyt-2-treated B 10 T cells exclusively induced allohelp, and the anti-Lyt-l-treated B 10 T cells were ineffective. These results are consistent with those reported elsewhere (12, 13) . Fig. 3 shows the different capacities of the same three suspensions of B10 T cells to induce LGVHD in irradiated BDF~ mice were used, because they irradiated F~ recipients are much more susceptible than nonirradiated ones to the induction of LGVHD (11, 16) . Whereas 90% of the F1 recipients of the NMS-treated B10 T cells developed LGVHD, only one (10%) of the recipients of anti-Lyt-2-treated T cells died, and none of the F1 recipients of anti-Lyt-1-treated B10 T cells died.
Subset of Donor T Cells Causing Chronic GVHD in Irradiated F1
Mice. The same groups of irradiated BDFI mice that had been used for studying LGVHD were also used for testing the presence of SLE-like autoantibodies in the serum (Table  II) . None of the F~ recipients that died from acute GVHD before the end of the . As a source of T cells, graded numbers of live B 10 spleen cells that had been treated twice, as indicated, were used; after the second treatment, these cells were passed through nylon-wool columns, adjusted to the same number of live cells, and added to the B cell cultures. The three T-cell suspensions tested here are the same that were used to perform the GVH experiments described in Fig. 3 and Table II . observation period (week 16) had shown autoantibodies before they died. In Table II antibodies. In contrast, neither N MS-treated nor anti-Lyt-l-treated B10 T cells were capable of inducing a comparable autoantibody formation in the recipients.
Discussion
The results of the present study indicate that, depending on the Lyt phenotype of the parental T lymphocytes injected, the F1 recipients developed either acute or chronic GVHD.
Stimulatory or Chronic GVHD. In previous studies, it was shown that injection into nonirradiated BDF1 recipients of unseparated B 10 T cells led to only limited autoantibody formation (2) and failed to induce ICGN but, instead, caused acute GVHD and LGVHD (10) . Using the same parent ---* F~ combination, now we showed that depletion of the allosuppressive Lyt-2 + cells rendered the B 10 donor cells capable of inducing a severe SLE-like autoimmune disease that included the development of ICGN (Table I ). The mechanism underlying the formation of autoantibodies during the GHVR is thought to be a positive allogeneic effect caused by abnormal T-B-cell cooperation (3, 7, 8, (17) (18) (19) (20) (21) . In this process, T cell help is provided by parental T cells that react against the allogeneic class-II (I-A/I-E) antigens of the F1 recipient's H-2 complex (3, 8) . The excess of T cell help generated by this reaction, in combination with certain self-antigens, triggers those F~ B cells capable of producing autoantibodies characteristic of SLE (3, 7, 8, 17, 21) . The autoantibodies in turn form immune complexes and cause ICGN (9) . In the present study, we showed that the production of multiple autoantibodies and ICGN during a GVHR requires the injection of Lyt-l+2 -donor cells; that Lyt phenotype is commonly associated with T n cells (15, 22, 23) , including the T n cells that react against allogeneic class-II antigens ( Fig. 2; 12, 13 ). In contrast, the B10 cells that had been pretreated with anti-Lyt-1 were unable to induce vigorous autoantibody formation in the recipients (Table I and II) . The latter finding is hardly surprising, however, because virtually all T cells express at least small amounts of Lyt-1 (24) . The low level of antinuclear antibodies observed after the injection of anti-Lyt-1-treated cells barely exceeded that found in syngeneically injected or noninjected BDF~ mice. This low level of spontaneous autoantibody formation conforms with previous reports (25, 26) that normal mice, especially at higher ages, may have antinuclear antibodies in the serum.
The different forms of GVHD induced by different Lyt subsets of donor T cells argue against the pathogenesis of chronic GVHD postulated by Elkins (1, 27) . He proposed that the symptoms of chronic GVHD are only late indirect consequences of the cytotoxic damage and the subsequent infections caused by the initial alloaggression by donor T cells. The data presented in the present paper, however, as well as other data (2-4, 7, 8) indicate that stimulatory GVH symptoms can appear already at 2 wk after the initiation of the GVHR and do not require a preceding phase of lymphohemopoietic depletion (acute GVHD); instead, these symptoms are direct consequences of the allo-stimulation induced by donor T H cells. In fact, we observed that removing the Lyt-2 + donor T cells, the very cells that are needed for the induction of acute GVHD, was a prerequisite for the induction of SLE-like GVHD by B10 T cells. Nevertheless, viral infections, including those acquired during GVHD, might lead to a GVH-like pathogenesis so that their symptoms are (almost) indistinguishable from those caused by alloreactive donor T cells (6, 17, 21) .
Acute GVHD. Following an initial phase of stimulatory symptoms in the first week of the GVH R (1, 2), acute GVHD rapidly produces suppressive pathological symptoms, such as pancytopenia accompanied by aplastic anemia and hypogammaglobulinemia (1) (2) (3) (4) (5) 10) . This biphasic course has led us to the concept (2) that acute GVHD in H-2-different recipients is due to a sequential activation, first of class-II-reactive donor T n or T inducer cells and, thereafter, of class-I-reactive donor T s cells. The activated donor T H cells might cause the initial phase of stimulatory symptoms, and, analogous to other systems (14) , induce class-IIreactive donor T s cells. Optimally activated donor T s cells appear to cause the suppressive pathological symptoms of GVHD (2-4, 10, 28, 29) .
In the present paper, we showed the alloreactive B10 cells carrying the Lyt-1+2 -phenotype were unable, or almost unable, to induce acute GVHD and LGVHD in either nonirradiated or irradiated H-2-different F1 mice (Figs. 1 and  3 ). This finding is consistent with the results published by Korngold and Sprent (30) , who showed that Lyt-l+2 -donor T cells were unable to induce LGVHD in irradiated recipients differing from the donor at multiple non-H-2 loci. Our findings differ, however, from the studies reported by Valera et al. (16) . Valera et al. studied the Lyt phenotype of the donor T cells responsible for the induction of LGVHD in irradiated recipients, which differed from the donor at all of H-2 as well as non-H-2 loci. They found that treatment of the donor cells with antiLyt-2 did not protect the recipient mice from LGVHD. The most likely explanation for this discrepancy with our data is that the single anti-Lyt-2 treatment of the donor cells used by Valera et al. (16) was not sufficient to remove all of the Lyt-2 + T cells and that the few spared T cells were responsible for the observed LGVHD in the irradiated recipients. In our hands, a single treatment with anti-Lyt-2 or alloreactive T cells often proved to be ineffective in abolishing their allosuppressor capacity in vitro (data not shown). In fact, Valera et al. (16) reported that their treatment with anti-Lyt-2 did not completely abrogate the capacity of the donor cells to generate anti-host T killer cells in vitro. Others (15, 31) , by contrast, have shown that T cells properly depleted of Lyt-2 ÷ cells were no longer capable of generating cytotoxic T cells across an H-2 difference. The possibility that, indeed, a very low number of spared Lyt-2 ÷ T cells might have caused the LGVHD observed by Valera et al. (16) receives further support by previous findings made by Korngold and Sprent (11) . These authors observed that parental bone marrow cells, which contained as few as 0.3% mature T cells, i.e. 3 X 104 T cells, sufficed to induce LGVHD in irradiated F1 recipients that differed at multiple non-H-2 loci only. Moreover, very similar observations have recently been made in human recipients of HLA-different bone marrow grafts (32) .
In agreement with Korngold and Sprent (30) and Valera et al. (16) we found that Lyt-l-2 + T cells, too, are unable to induce LGVHD. Together with the observed inability of Lyt-1 +2-cells to induce LGVHD, the combined results lead to the conclusion that donor T cells carrying the Lyt-l+2 + phenotype must be involved in the pathogenesis of LGVHD. This conclusion is identical with that of Korngold and Sprent (30) . It is not yet known, however, whether Lyt-l+2 -inducer T cells are required in addition to the Lyt-l÷2 + donor cells.
As already mentioned, we think that alloreactive donor T s cells are the effector cells that cause the pancytopenia of acute GVHD (3, 4, 10). Our conclusion that donor Lyt-1 ÷2 + cells must be involved in the pathogenesis of LGVHD is consistent with this concept, because several groups of investigators showed that the severe aliosuppression at the beginning of the second phase of acute GVHD, i.e. at about day 7, is caused by Lyt-l+2 ÷ donor T cells (33) (34) (35) . Furthermore, recently we provided evidence that allosuppression induced in vitro also requires Lyt-l+2 + cells, because neither Lyt-l-2 + cells alone nor a mixture consisting of Lyt-l+2 -cells and increasing numbers of Lyt-l-2 ÷ cells were able to induce allosuppression across a full H-2 difference (13). These studies also showed that a class-II-reactive Lyt-l+2 -cell causes allohelp, whereas allosuppression in vitro appears to be caused by a class-I-reactive Lyt-l+2 + cells. Thus, the data of the present study have closed the gap between the studies performed in vitro (13) and the GVH experiments performed in vivo. In combination with previous findings (3, 8) , we conclude that stimulatory GVHD is caused by class-II-reactive Lyt-l+2 -donor T H cells. In contrast, the development of suppressive GVHD seems to require class-I-reactive Lyt-l÷2 + T s cells and, possibly also class IIreactive Lyt-l+2 -inducer cells of the donor. However, experiments involving positively selected Lyt-1 +2 ÷ ceils will have to be performed in order to verify this concept.
Summary
Previous work from this laboratory has led to the hypothesis that the stimulatory pathological symptoms of chronic graft-vs.-host disease (GVHD) are caused by ailoreactive donor T helper (T n) cells, whereas the suppressive pathological symptoms of acute GVHD are caused by alloreactive T suppressor (T s) cells of the donor. In the present paper we analyzed the Lyt phenotypes of B10 donor T cells required for the induction of either acute or chronic GVHD in H-2-different (B 10 x DBA/2)F1 recipients. First, nonirradiated F1 mice were used as the recipients. We found that unseparated B 10 T cells induced only a moderate formation of systemic lupus erythematosus (SLE)-like autoantibodies, but a high percentage of lethal GVHD (LGVHD). In contrast, Lyt-1 +2-donor T cells were unable to induce LGVHD in these recipients; these cells were capable, however, of inducing a vigorous formation of SLE-like autoantibodies and the formation of severe immune-complex glomerulonephritis. Lyt-l-2 + T cells were incapable of inducing either acute or chronic GVHD.
In another experiment, the sensitivity and accuracy of the GVH system were increased by using irradiated F1 mice as recipients and by comparing donor-cell inocula that contained similar numbers of T lymphocytes. In addition, donorcell inocula were used that had been tested for their alloheiper and allosuppressor effects on F~ B cells in vitro. In the irradiated FI recipients, too, unseparated donor T cells were superior to T cell subsets in inducing LGVHD; Lyt-l-2 + donor cells were completely and Lyt-1 +2-donor cells were almost incapable of doing so. In contrast, Lyt-l+2 -T cells, but neither unseparated T cells nor Lyt-1-2 + T cells, were capable of inducing a vigorous formation of SLE-like autoantibodies. We conclude that the stimulatory pathological symptoms of chronic GVHD are caused by Lyt-l+2 -allohelper T cells. In contrast, the development of the suppressive pathological symptoms of acute GVHD appears to involve ailoreactive Lyt-1 +2 + T suppressor cells.
